GSA Capital Partners LLP Buys 60,018 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Key Points

• GSA Capital Partners LLP increased its stake in Arrowhead Pharmaceuticals by 514.4%, acquiring 60,018 additional shares and bringing its total to approximately 71,685 shares worth $913,000.
• Several institutional investors, including Norges Bank and Raymond James Financial Inc., made significant investments in Arrowhead Pharmaceuticals in the fourth quarter, indicating strong institutional interest.
• Analysts have mixed opinions on Arrowhead Pharmaceuticals, with ratings ranging from "strong-buy" to "hold," while the company has a consensus price target of $43.71.

GSA Capital Partners LLP raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 514.4% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 71,685 shares of the biotechnology company's stock after buying an additional 60,018 shares during the period. GSA Capital Partners LLP owned about 0.05% of Arrowhead Pharmaceuticals worth $913,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $651,000. KLP Kapitalforvaltning AS bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $434,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Arrowhead Pharmaceuticals by 23.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 13,281 shares of the biotechnology company's stock worth $263,000 after buying an additional 2,556 shares during the period. Norges Bank bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $38,622,000. Finally, Headlands Technologies LLC lifted its holdings in Arrowhead Pharmaceuticals by 15.3% in the fourth quarter. Headlands Technologies LLC now owns 20,749 shares of the biotechnology company's stock valued at $390,000 after buying an additional 2,750 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Citigroup decreased their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $43.71.

Arrowhead Pharmaceuticals Trading Up 0.6%

NASDAQ:ARWR opened at $15.80 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.15 and a quick ratio of 5.15. The business's 50-day simple moving average is $16.41 and its 200-day simple moving average is $16.11. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $29.47. The stock has a market capitalization of $2.18 billion, a PE ratio of -11.29, a price-to-earnings-growth ratio of 18.47 and a beta of 0.93.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same quarter last year, the business posted ($1.02) earnings per share. Sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.